R&D Partner Content 8th Gene Therapy Development Summit With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining mome
R&D Partner Content 10th Innate Killer Summit With recent expansion into autoimmune pipelines, the year of the ‘bounce back’ now feels in reach for the NK space.
R&D Partner Content 4th Cell Therapy Potency Assay Summit In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical.
Oncology Partner Content 9th Liquid Biopsy for Precision Oncology Summit 9th Liquid Biopsy for Precision Oncology Summit | February 18-20, 2025 | San Diego, CA | FREE* to Attend for Biopharma
R&D Partner Content 9th Commercialising Continuous Processing Summit 2025 The pivotal shift in biopharma priorities is steering towards enhancing sustainability measures for drug development.
R&D Partner Content Returning... The 5th Operationalize Expanded Access Programs... Welcome to, or welcome back to, the 5th Operationalize: Expanded Access Programs Summit 2025!
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.